Literature DB >> 6179458

Neuroimmunology I: Immunoregulation in neurological disease.

H L Weiner, S L Hauser.   

Abstract

Aberrations in immune function that ultimately result in disease states may involve three aspects of immune regulation: (1) regulatory T cells, which both suppress and induce immune responses; (2) idiotype-antiidiotype networks, which serve as internal regulatory networks during generation of an immune response; and (3) immune response genes, which determine genetic differences in an individual's immune response. Three major diseases of the nervous system, multiple sclerosis, myasthenia gravis, and acute inflammatory polyneuropathy (Guillain-Barré syndrome), are classified as "autoimmune" in nature and may be due to underlying disorders of immunoregulation. In multiple sclerosis there is a loss of suppressor T cells in the peripheral blood during attacks, in myasthenia gravis there are thymic abnormalities and antibodies against the acetylcholine receptor, and in acute inflammatory polyneuropathy, macrophage-mediated destruction of peripheral nerve myelin occurs in the context of sensitized T cells and is usually associated with a preceding viral illness. In each of these diseases the following central questions must be answered: (1) against what antigen (or antigens) of the nervous system is the autoimmune response directed? (2) what is the mechanism of immune damage? and (3) what initiates, or triggers, the autoimmune response?

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6179458     DOI: 10.1002/ana.410110502

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  25 in total

Review 1.  Statins as potential therapeutic agents in multiple sclerosis.

Authors:  Olaf Stüve; Thomas Prod'homme; Sawsan Youssef; Shannon Dunn; Oliver Neuhaus; Martin Weber; Hans-Peter Hartung; Lawrence Steinman; Scott S Zamvil
Journal:  Curr Neurol Neurosci Rep       Date:  2004-05       Impact factor: 5.081

Review 2.  Astrocytes and intracerebral immune responses.

Authors:  E M Frohman; S van den Noort; S Gupta
Journal:  J Clin Immunol       Date:  1989-01       Impact factor: 8.317

3.  The science of clinical neurology.

Authors:  J Walton
Journal:  J R Soc Med       Date:  1986-01       Impact factor: 5.344

4.  T-lymphocyte subsets modifications in multiple sclerosis: correlation with clinical disease activity.

Authors:  M Prencipe; E Salerni; C D'Aurizio; C Marini; D Adorno; A M Berghella; P Pellegrini; F Papola; C U Casciani
Journal:  Ital J Neurol Sci       Date:  1986-12

5.  Murine monoclonal antibodies to the myelin-associated glycoprotein react with large granular lymphocytes of human blood.

Authors:  M J Dobersen; P Gascon; S Trost; J A Hammer; S Goodman; A B Noronha; D J O'Shannessy; R O Brady; R H Quarles
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

6.  Short-term intensive cyclophosphamide treatment in progressive multiple sclerosis.

Authors:  G F Siracusa; M P Amato; L Fratiglioni; D Sità; L Amaducci
Journal:  Ital J Neurol Sci       Date:  1987-12

7.  Free light chains in the cerebrospinal fluid: an indicator of recent immunological stimulation.

Authors:  A Vakaet; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-10       Impact factor: 10.154

Review 8.  The endothelium--astrocyte immune control system of the brain.

Authors:  A Fontana; W Fierz
Journal:  Springer Semin Immunopathol       Date:  1985

9.  An association between multiple sclerosis and type I diabetes mellitus.

Authors:  E Wertman; N Zilber; O Abramsky
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

10.  Monoclonal antibody analysis of blood T-cell subsets in multiple sclerosis.

Authors:  M Zaffaroni; D Caputo; A Ghezzi; S Marforio; C L Cazzullo
Journal:  Ital J Neurol Sci       Date:  1984-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.